Ceregene Company Profile
Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of neurotrophic (or nervous system growth) factors for the treatment of neurodegenerative and retinal disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor currently in a multi-center, controlled Phase 2 study for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) for Parkinson's disease. CERE-140 is in preclinical development for several blinding, ocular disorders. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and BioSante Pharmaceuticals (Nasdaq: BPAX) which acquired its position following its merger with Cell Genesys, Inc. in October 2009, as well as Hamilton BioVentures and California Technology Partners.
News Articles
Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study
SAN DIEGO, May 21, 2013 /PRNewswire/ -- Ceregene, Inc. today announced additional efficacy data from a secondary analysis of its double-blind, randomized, controlled Phase 2b clinical study of CERE-12...
Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase ...
SAN DIEGO, March 13, 2013 /PRNewswire/ -- Ceregene, Inc. today announced the completion of enrollment in its double-blind Phase 2 clinical study of CERE-110 (AAV-NGF), a gene therapy product designed...
Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease
Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neuro...
Ceregene Reports Data From Parkinson's Disease Phase 2b Study
SAN DIEGO, April 19, 2013 /PRNewswire/ -- Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a g...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Using gene therapy delivery systems, Ceregene's primary focus is the discovery and development of novel genetic therapeutics for the treatment of neurological disorders. Ceregene aims to be the leader...
Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of neurotrophic (or nervous system growth) factors for the treatment of neurodegenerative and retinal disorders using...
Cell Genesys is a leader in the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies. The company has a broad portfolio of clinical stage...
More Information about "Ceregene" on BioPortfolio
We have published hundreds of Ceregene news stories on BioPortfolio along with dozens of Ceregene Clinical Trials and PubMed Articles about Ceregene for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ceregene Companies in our database. You can also find out about relevant Ceregene Drugs and Medications on this site too.
